The DOI matches its Crossref record; 32 of the 32 references it cites were found in a registry or an index.
Optimization of brain targeted chitosan nanoparticles of Rivastigmine for improved efficacy and safety
Abstract
The study aims at formulation and optimization brain targeted nanoparticles (NP) of Rivastigmine (RT) to improve its therapeutic potential and to verify its safety profile. The NP were optimized using a two factor three level (3(2)) central composite design aiming to minimize particle size; maximize zeta potential and drug entrapment efficiency of NP. The optimized formulation (cRTNP) was evaluated using in vitro drug release study; in vivo behavioral, and biochemical and maximum tolerated dose (MTD) study. The optimized formulation evidenced a significant reversal of scopolamine-induced amnesia by Tween 80(®) coated nanoparticles as compared to both pure RT as well as uncoated nanoparticles. The MTD of RT was increased by 10% by formulating them as cRTNP. Thus, formulation of RT as cRTNP improved the therapeutic and safety profile of RT.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, RT-loaded chitosan NPs also improved memory function with reduced toxicity in a mouse model.102”
From Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles (2019) · cites this paper as [102]
Citations
Cites
International Journal of Nanomedicine
(2020) · International Journal of Nanomedicine · doi:10.2147/ijn · Cited by 2,760
Irwin, S. (1968) · Psychopharmacology · doi:10.1007/bf00401402 · Cited by 1,240
Iranian Journal of Pharmaceutical Research
(2022) · Iranian journal of pharmaceutical research · doi:10.5812/ijpr · Cited by 1,229
Pardridge, W. M. (2007) · Drug Discovery Today · doi:10.1016/j.drudis.2006.10.013 · Cited by 1,191
Chitosan Nanoparticles: A Promising System in Novel Drug Delivery
Nagpal, K., Singh, S. K., & Mishra, D. N. (2010) · Chemical and Pharmaceutical Bulletin · doi:10.1248/cpb.58.1423 · Cited by 661
Self-citationZensi, A., Begley, D., Pontikis, C., Legros, C., Mihoreanu, L., Wagner, S., Büchel, C., von Briesen, H., & Kreuter, J. (2009) · Journal of Controlled Release · doi:10.1016/j.jconrel.2009.03.002 · Cited by 438
New Acetylcholinesterase Inhibitors for Alzheimer's Disease
Mehta, M., Adem, A., & Sabbagh, M. N. (2011) · International Journal of Alzheimer s Disease · doi:10.1155/2012/728983 · Cited by 436
Development and evaluation of rivastigmine loaded chitosan nanoparticles for brain targeting
Fazil, M., Md, S., Haque, S., Kumar, M., Baboota, S., Sahni, J. K., & Ali, J. (2012) · European Journal of Pharmaceutical Sciences · doi:10.1016/j.ejps.2012.04.013 · Cited by 379
Nerurkar, M. M., Burton, P. S., & Borchardt, R. T. (1996) · Pharmaceutical Research · doi:10.1023/a:1016033702220 · Cited by 287
Wagner, S., Zensi, A., Wien, S., Tschickardt, S., Maier, W., Vogel, T., Worek, F., Pietrzik, C. U., Kreuter, J., & von Briesen, H. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032568 · Cited by 265
Research works printed but not linked: 4
- Chhillar, 2012, Fundamental and Clinical Pharmacology
- Nagpal, 2012, Inventi Rapid: NDDS, 1
- da Volta Soares, 2011, International Journal of Nanomedicine, 6, 227
- Tian, 2011, International Journal of Nanomedicine, 6, 445
Cited by
Sorted by citations
Targeted therapy in chronic diseases using nanomaterial-based drug delivery vehicles
Singh, A. P., Biswas, A., Shukla, A., & Maiti, P. (2019) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-019-0068-3 · Cited by 645
Chitosan in nasal delivery systems for therapeutic drugs
Casettari, L., & Illum, L. (2014) · Journal of Controlled Release · doi:10.1016/j.jconrel.2014.05.003 · Cited by 448
Elnaggar, Y. S. R., Etman, S. M., Abdelmonsif, D. A., & Abdallah, O. Y. (2015) · Journal of Pharmaceutical Sciences · doi:10.1002/jps.24557 · Cited by 333
Jurcău, M. C., Andronie-Cioara, F. L., Jurcău, A., Marcu, F., Ţiț, D. M., Pașcalău, N., & Nistor-Cseppentö, D. C. (2022) · Antioxidants · doi:10.3390/antiox11112167 · Cited by 226
Bugnicourt, L., & Ladavière, C. (2016) · Progress in Polymer Science · doi:10.1016/j.progpolymsci.2016.06.002 · Cited by 202
Metadata
- Authors
- Nagpal, K., Singh, S. K., & Mishra, D. N.
- Affiliations
- Guru Jambheshwar University of Science and Technology (IN)
- Corresponding author
- Nagpal, Kalpana
- Venue
- International Journal of Biological Macromolecules
- Publisher
- Elsevier BV
- Published
- 2013-08
- Volume
- 59
- Pages
- 72-83
- ISSN
- 0141-8130 (ISSN-L)
- OpenAlex
- W2024268060
- Cited by
- 116
- References
- 32
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 11 · 2023: 16 · 2022: 10 · 2021: 10 · 2020: 16 · 2019: 6 · 2018: 5 · 2017: 6 · 2016: 7 · 2015: 7 · 2014: 3 · 2013: 1
- FWCI
- 3.61
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- International Journal of Biological Macromolecules (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Pharmacology, Toxicology and Pharmaceutics › Pharmaceutical Science › Advanced Drug Delivery Systems
- Physical Sciences › Materials Science › Biomaterials › Nanoparticle-Based Drug Delivery
- Health Sciences › Medicine › Pharmacology (medical) › Cholinesterase and Neurodegenerative Diseases
- Keywords
- rivastigmine, chitosan nanoparticles, brain drug delivery, central composite design, scopolamine-induced amnesia, maximum tolerated dose, encapsulation efficiency, zeta potential, particle size, in vitro drug release, Alzheimer's disease
- MeSH terms
- Rivastigmine, Amnesia, Animals, Behavior, Animal, Body Weight, Brain, Dose-Response Relationship, Drug, Drug Carriers, Drug Compounding, Drug Evaluation, Preclinical, Factor Analysis, Statistical, Male, Memory, Polysorbates, Scopolamine, Treatment Outcome, Neuroprotective Agents, Maze Learning, Chitosan, Phenylcarbamates, Mice, Rats, Nanoparticles
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
